SG11201808541VA - Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use - Google Patents
Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and useInfo
- Publication number
- SG11201808541VA SG11201808541VA SG11201808541VA SG11201808541VA SG11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA
- Authority
- SG
- Singapore
- Prior art keywords
- rivig
- international
- immune
- proteins
- ste
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 238000001990 intravenous administration Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 235000018102 proteins Nutrition 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 abstract 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 101150067539 AMBP gene Proteins 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 241000282465 Canis Species 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 208000003807 Graves Disease Diseases 0.000 abstract 1
- 208000015023 Graves' disease Diseases 0.000 abstract 1
- 208000028622 Immune thrombocytopenia Diseases 0.000 abstract 1
- 208000011200 Kawasaki disease Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 101710141454 Nucleoprotein Proteins 0.000 abstract 1
- 206010037549 Purpura Diseases 0.000 abstract 1
- 241001672981 Purpura Species 0.000 abstract 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 abstract 1
- 238000010322 bone marrow transplantation Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 230000003210 demyelinating effect Effects 0.000 abstract 1
- 201000001981 dermatomyositis Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000036473 myasthenia Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940070376 protein Drugs 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 201000003067 thrombocytopenia due to platelet alloimmunization Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315483P | 2016-03-30 | 2016-03-30 | |
| PCT/US2017/024650 WO2017172853A1 (fr) | 2016-03-30 | 2017-03-29 | Compositions d'immunoglobuline intraveineuse recombinante (rivig) et leurs procédés de production et d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808541VA true SG11201808541VA (en) | 2018-10-30 |
Family
ID=59965144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808541VA SG11201808541VA (en) | 2016-03-30 | 2017-03-29 | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11304994B2 (fr) |
| EP (1) | EP3436484A4 (fr) |
| JP (1) | JP7075100B2 (fr) |
| KR (1) | KR102477536B1 (fr) |
| CN (1) | CN109312000A (fr) |
| AU (1) | AU2017245143B2 (fr) |
| BR (1) | BR112018070022A2 (fr) |
| CA (1) | CA3019530A1 (fr) |
| CL (1) | CL2018002769A1 (fr) |
| CO (1) | CO2018011457A2 (fr) |
| EA (1) | EA201891999A1 (fr) |
| IL (1) | IL261968A (fr) |
| MA (1) | MA44517A (fr) |
| MX (1) | MX2018011865A (fr) |
| SG (1) | SG11201808541VA (fr) |
| TW (1) | TWI801336B (fr) |
| WO (1) | WO2017172853A1 (fr) |
| ZA (1) | ZA201806767B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3723791B1 (fr) | 2017-12-14 | 2024-02-21 | CSL Behring Lengnau AG | Multimères de fc d'igg de recombinaison pour le traitement de la neuromyélite optique |
| WO2020077298A1 (fr) * | 2018-10-11 | 2020-04-16 | Momenta Pharmaceuticals, Inc. | Traitement avec des compositions d'igg hautement sialylées |
| KR20210110563A (ko) * | 2018-10-18 | 2021-09-08 | 킨드레드 바이오사이언시스, 인코포레이티드 | 수의학적 용도를 위한 신생아 fc 수용체(fcrn)에 변경된 결합을 갖는 fc 변이체 |
| CN109793894A (zh) * | 2019-04-03 | 2019-05-24 | 长春西诺生物科技有限公司 | 犬免疫球蛋白在制备犬溶血性贫血药物中的应用 |
| KR20220062084A (ko) | 2019-09-13 | 2022-05-13 | 체에스엘 베링 렝나우 아게 | 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체 |
| CN112899301B (zh) * | 2021-01-29 | 2023-04-11 | 中国热带农业科学院热带生物技术研究所 | 一种木薯普通花叶病毒诱导的基因沉默系统及其应用 |
| CN117964777A (zh) * | 2021-08-26 | 2024-05-03 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100497849B1 (ko) * | 1997-08-21 | 2005-06-29 | 다카라 바이오 가부시키가이샤 | 제암제 |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| WO2002072608A2 (fr) | 2001-03-09 | 2002-09-19 | University Of Chicago | Proteines hybrides d'immunoglobulines polymeriques ciblant des recepteurs fc$g(g) a faible affinite |
| US7279329B2 (en) * | 2005-10-17 | 2007-10-09 | Industrial Technology Research Institute | Expression system for producing collagen |
| US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| CA2682605A1 (fr) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Fc a chaine simple, procedes de fabrication et procedes de traitement |
| BRPI0811857A2 (pt) * | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| ES2565834T3 (es) | 2007-06-01 | 2016-04-07 | University Of Maryland, Baltimore | Agentes de unión a receptor de Fc de región constante de inmunoglobulina |
| WO2010065578A2 (fr) | 2008-12-04 | 2010-06-10 | Leukosight Inc. | Polypeptides comprenant des fragments fc de l'immunoglobuline g (igg) et leurs procédés d'utilisation |
| MX368531B (es) * | 2010-07-28 | 2019-10-07 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
| EP2561888A1 (fr) | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protéine comprenant NC-1 pour traiter des maladies liées à l'angiogenèse |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| US9962436B2 (en) * | 2012-07-26 | 2018-05-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
| EP2885320A4 (fr) | 2012-08-20 | 2016-04-06 | Gliknik Inc | Molécules présentant une activité de liaison à l'antigène et de liaison aux récepteurs polyvalents fc gamma |
| US20150218236A1 (en) * | 2012-10-17 | 2015-08-06 | Liverpool School Of Tropical Medicine | Immunomodulatory proteins |
| PT2968461T (pt) | 2013-03-13 | 2022-12-26 | Genzyme Corp | Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| WO2015158867A1 (fr) | 2014-04-16 | 2015-10-22 | Ucb Biopharma Sprl | Protéines fc multimères |
| WO2017024114A1 (fr) | 2015-08-06 | 2017-02-09 | President And Fellows Of Harvard College | Molécules améliorées aptes à se lier à des microbes, et leurs utilisations |
-
2017
- 2017-03-29 CA CA3019530A patent/CA3019530A1/fr active Pending
- 2017-03-29 JP JP2019503393A patent/JP7075100B2/ja active Active
- 2017-03-29 CN CN201780033114.8A patent/CN109312000A/zh active Pending
- 2017-03-29 BR BR112018070022A patent/BR112018070022A2/pt unknown
- 2017-03-29 US US16/089,042 patent/US11304994B2/en active Active
- 2017-03-29 EA EA201891999A patent/EA201891999A1/ru unknown
- 2017-03-29 MA MA044517A patent/MA44517A/fr unknown
- 2017-03-29 MX MX2018011865A patent/MX2018011865A/es unknown
- 2017-03-29 SG SG11201808541VA patent/SG11201808541VA/en unknown
- 2017-03-29 KR KR1020187030960A patent/KR102477536B1/ko active IP Right Grant
- 2017-03-29 EP EP17776516.1A patent/EP3436484A4/fr active Pending
- 2017-03-29 AU AU2017245143A patent/AU2017245143B2/en active Active
- 2017-03-29 WO PCT/US2017/024650 patent/WO2017172853A1/fr active Application Filing
- 2017-03-30 TW TW106110897A patent/TWI801336B/zh active
-
2018
- 2018-09-26 IL IL261968A patent/IL261968A/en unknown
- 2018-09-28 CL CL2018002769A patent/CL2018002769A1/es unknown
- 2018-10-11 ZA ZA2018/06767A patent/ZA201806767B/en unknown
- 2018-10-26 CO CONC2018/0011457A patent/CO2018011457A2/es unknown
-
2022
- 2022-03-29 US US17/707,243 patent/US11801286B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201806767B (en) | 2023-04-26 |
| EA201891999A1 (ru) | 2019-08-30 |
| BR112018070022A2 (pt) | 2019-02-05 |
| US20220233658A1 (en) | 2022-07-28 |
| WO2017172853A1 (fr) | 2017-10-05 |
| US20190111115A1 (en) | 2019-04-18 |
| TWI801336B (zh) | 2023-05-11 |
| MX2018011865A (es) | 2019-03-28 |
| CA3019530A1 (fr) | 2017-10-05 |
| US11801286B2 (en) | 2023-10-31 |
| CL2018002769A1 (es) | 2018-12-28 |
| IL261968A (en) | 2018-10-31 |
| JP7075100B2 (ja) | 2022-05-25 |
| JP2019513024A (ja) | 2019-05-23 |
| AU2017245143B2 (en) | 2024-01-11 |
| TW201741335A (zh) | 2017-12-01 |
| US11304994B2 (en) | 2022-04-19 |
| EP3436484A1 (fr) | 2019-02-06 |
| KR102477536B1 (ko) | 2022-12-13 |
| CO2018011457A2 (es) | 2019-02-08 |
| EP3436484A4 (fr) | 2019-12-04 |
| KR20180132731A (ko) | 2018-12-12 |
| MA44517A (fr) | 2019-02-06 |
| AU2017245143A1 (en) | 2018-10-18 |
| CN109312000A (zh) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808541VA (en) | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201803975SA (en) | Improved tnf binders | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| SG11201901790YA (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |